# Monoclonal Antibody Therapy and Docetaxel in Treating Women With Metastatic or Recurrent Breast Cancer

> **NCT00028483** · PHASE2 · TERMINATED · sponsor: **Seagen Inc.**

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** cBR96-doxorubicin immunoconjugate
- **DRUG:** docetaxel

## Key facts

- **NCT ID:** NCT00028483
- **Lead sponsor:** Seagen Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2000-10
- **Primary completion:** —
- **Final completion:** 2003-04
- **Target enrollment:** — (—)
- **Last updated:** 2011-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00028483

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00028483, "Monoclonal Antibody Therapy and Docetaxel in Treating Women With Metastatic or Recurrent Breast Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00028483. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*